ArticleMolecular and clinical oncology2025
Clinical manifestation and pathological changes of serous papillary adenofibroma: A case series.
Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serous papillary adenofibroma (SPAF) is a rare benign tumor in gynecological practice. Most patients have no symptoms and occasionally present with pelvic masses during physical examinations. SPAF consists of both fibrous and epithelial parts, which makes it easy to misdiagnose malignancies on pre-surgery examinations. Therefore, clinical and pathological features of SPAF at the Second Affiliated Hospital Zhejiang University School of Medicine (Hangzhou, China) were summarized in the present study to assist clinical practice. A total of 13 cases encountered at our hospital were collected and immunohistochemistry (IHC) staining was performed on their specimens. SPAF appears as a unilocular cystic mass on imaging. Serum estradiol and prolactin levels were elevated in certain patients. The IHC staining of SPAF was estrogen receptor-, progesterone receptor- and human epidermal growth factor receptor 2-positive but Ki-67- and p53-negative. The present study proved the sex hormone sensitivity of SPAF and the benign prognosis of patients. Magnetic resonance imaging is a promising method for differential diagnosis before surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.